Loading...
Header Logo
Keywords
Last Name
Institution

LORETTA A WILLIAMS

TitleAssistant Professor
InstitutionMD Anderson
DepartmentSymptom Research CAO
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Whisenant MS, Strunk FA, Tripathy D, Williams LA. What symptoms are important to patients? Developing a symptom burden measure for women with breast cancer. Support Care Cancer. 2019 Apr 02. PMID: 30937601.
      View in: PubMed
    2. Bashir Q, Thall PF, Milton DR, Fox PS, Kawedia JD, Kebriaei P, Shah N, Patel K, Andersson BS, Nieto YL, Valdez BC, Parmar S, Rondon G, Delgado R, Hosing C, Popat UR, Oran B, Ciurea SO, Lin P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Williams LA, Champlin RE, Qazilbash MH. Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial. Lancet Haematol. 2019 May; 6(5):e266-e275. PMID: 30910541.
      View in: PubMed
    3. Wang XS, Shi Q, Williams LA, Cleeland CS, Garcia-Gonzalez A, Chen TY, Shahid DR, Ramirez PT, Iniesta MD, Siverand AM, Meyer LA. Validation and application of a module of the MD Anderson Symptom Inventory for measuring perioperative symptom burden in patients with gynecologic cancer (the MDASI-PeriOp-GYN). Gynecol Oncol. 2019 03; 152(3):492-500. PMID: 30876494.
      View in: PubMed
    4. Mendoza TR, Kehl KL, Bamidele O, Williams LA, Shi Q, Cleeland CS, Simon G. Assessment of baseline symptom burden in treatment-naïve patients with lung cancer: an observational study. Support Care Cancer. 2019 Jan 19. PMID: 30661202.
      View in: PubMed
    5. Zulbaran-Rojas A, Lin HK, Shi Q, Williams LA, George B, Garcia-Manero G, Jabbour E, O'Brien S, Ravandi F, Wierda W, Estrov Z, Borthakur G, Kadia T, Cleeland C, Cortes JE, Kantarjian H. A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors. Cancer Med. 2018 Nov; 7(11):5457-5469. PMID: 30318751.
      View in: PubMed
    6. Williams LA, Whisenant MS, Mendoza TR, Haq S, Keating KN, Cuffel B, Cleeland CS. Modification of existing patient-reported outcome measures: qualitative development of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM). Qual Life Res. 2018 Dec; 27(12):3229-3241. PMID: 30187393.
      View in: PubMed
    7. Williams LA, Garcia-Gonzalez A, Mendoza TR, Haq S, Cleeland CS. Concept domain validation and item generation for the Treatment-Induced Neuropathy Assessment Scale (TNAS). Support Care Cancer. 2019 Mar; 27(3):1021-1028. PMID: 30094731.
      View in: PubMed
    8. Khoury HJ, Williams LA, Atallah E, Hehlmann R. Chronic Myeloid Leukemia: What Every Practitioner Needs to Know in 2017. Am Soc Clin Oncol Educ Book. 2017; 37:468-479. PMID: 28561719.
      View in: PubMed
    9. Williams LA, Bohac C, Hunter S, Cella D. Patient and health care provider perceptions of cancer-related fatigue and pain. Support Care Cancer. 2016 10; 24(10):4357-63. PMID: 27207616.
      View in: PubMed
    10. Wang XS, Shi Q, Dougherty PM, Eng C, Mendoza TR, Williams LA, Fogelman DR, Cleeland CS. Prechemotherapy Touch Sensation Deficits Predict Oxaliplatin-Induced Neuropathy in Patients with Colorectal Cancer. Oncology. 2016; 90(3):127-35. PMID: 26882477.
      View in: PubMed
    11. Wang XS, Shi Q, Williams LA, Komaki R, Gomez DR, Lin SH, Chang JY, O'Reilly MS, Bokhari RH, Cox JD, Mohan R, Cleeland CS, Liao Z. Prospective Study of Patient-Reported Symptom Burden in Patients With Non-Small-Cell Lung Cancer Undergoing Proton or Photon Chemoradiation Therapy. J Pain Symptom Manage. 2016 05; 51(5):832-8. PMID: 26891607.
      View in: PubMed
    12. Shah N, Shi Q, Williams LA, Mendoza TR, Wang XS, Reuben JM, Dougherty PM, Bashir Q, Qazilbash MH, Champlin RE, Cleeland CS, Giralt SA. Higher Stem Cell Dose Infusion after Intensive Chemotherapy Does Not Improve Symptom Burden in Older Patients with Multiple Myeloma and Amyloidosis. Biol Blood Marrow Transplant. 2016 Feb; 22(2):226-231. PMID: 26253006.
      View in: PubMed
    13. Mendoza TR, Wang XS, Williams LA, Shi Q, Vichaya EG, Dougherty PM, Thomas SK, Yucel E, Bastida CC, Woodruff JF, Cleeland CS. Measuring Therapy-Induced Peripheral Neuropathy: Preliminary Development and Validation of the Treatment-Induced Neuropathy Assessment Scale. J Pain. 2015 Oct; 16(10):1032-43. PMID: 26210041.
      View in: PubMed
    14. Meyer LA, Nick AM, Shi Q, Wang XS, Williams L, Brock T, Iniesta MD, Rangel K, Lu KH, Ramirez PT. Perioperative trajectory of patient reported symptoms: a pilot study in gynecologic oncology patients. Gynecol Oncol. 2015 Mar; 136(3):440-5. PMID: 25647455.
      View in: PubMed
    15. Shi Q, Wang XS, Li G, Shah ND, Orlowski RZ, Williams LA, Mendoza TR, Cleeland CS. Racial/ethnic disparities in inflammatory gene single-nucleotide polymorphisms as predictors of a high risk for symptom burden in patients with multiple myeloma 1 year after diagnosis. Cancer. 2015 Apr 01; 121(7):1138-46. PMID: 25469832.
      View in: PubMed
    16. Wang XS, Shi Q, Williams LA, Shah ND, Mendoza TR, Cohen EN, Reuben JM, Cleeland CS, Orlowski RZ. Longitudinal analysis of patient-reported symptoms post-autologous stem cell transplant and their relationship to inflammation in patients with multiple myeloma. Leuk Lymphoma. 2015 May; 56(5):1335-41. PMID: 25248883.
      View in: PubMed
    17. Cleeland CS, Williams LA. Symptom burden in hematologic malignancies. Blood. 2014 Jun 12; 123(24):3686-7. PMID: 24926067.
      View in: PubMed
    18. Wang XS, Shi Q, Shah ND, Heijnen CJ, Cohen EN, Reuben JM, Orlowski RZ, Qazilbash MH, Johnson VE, Williams LA, Mendoza TR, Cleeland CS. Inflammatory markers and development of symptom burden in patients with multiple myeloma during autologous stem cell transplantation. Clin Cancer Res. 2014 Mar 01; 20(5):1366-74. PMID: 24423611.
      View in: PubMed
    19. Williams LA, Yucel E, Cortes JE, Cleeland CS. Measuring symptoms as a critical component of drug development and evaluation in hematological diseases. Clin Investig (Lond). 2013 Dec 01; 3(12):1127-1138. PMID: 24910769.
      View in: PubMed
    20. Williams LA, Garcia Gonzalez AG, Ault P, Mendoza TR, Sailors ML, Williams JL, Huang F, Nazha A, Kantarjian HM, Cleeland CS, Cortes JE. Measuring the symptom burden associated with the treatment of chronic myeloid leukemia. Blood. 2013 Aug 01; 122(5):641-7. PMID: 23777764.
      View in: PubMed
    21. Sailors MH, Bodurka DC, Gning I, Ramondetta LM, Williams LA, Mendoza TR, Agarwal S, Sun CC, Cleeland CS. Validating the M. D. Anderson Symptom Inventory (MDASI) for use in patients with ovarian cancer. Gynecol Oncol. 2013 Aug; 130(2):323-8. PMID: 23685012.
      View in: PubMed
    22. Williams LA, Agarwal S, Bodurka DC, Saleeba AK, Sun CC, Cleeland CS. Capturing the patient's experience: using qualitative methods to develop a measure of patient-reported symptom burden: an example from ovarian cancer. J Pain Symptom Manage. 2013 Dec; 46(6):837-45. PMID: 23615044.
      View in: PubMed
    23. Vichaya EG, Wang XS, Boyette-Davis JA, Mendoza TR, He Z, Thomas SK, Shah N, Williams LA, Cleeland CS, Dougherty PM. Subclinical pretreatment sensory deficits appear to predict the development of pain and numbness in patients with multiple myeloma undergoing chemotherapy. Cancer Chemother Pharmacol. 2013 Jun; 71(6):1531-40. PMID: 23543296.
      View in: PubMed
    24. Jones D, Vichaya EG, Wang XS, Williams LA, Shah ND, Thomas SK, Johnson VE, Champlin RE, Cleeland CS, Mendoza TR. Validation of the M. D. Anderson Symptom Inventory multiple myeloma module. J Hematol Oncol. 2013 Feb 05; 6:13. PMID: 23384030.
      View in: PubMed
    25. Cleeland CS, Sloan JA, Cella D, Chen C, Dueck AC, Janjan NA, Liepa AM, Mallick R, O'Mara A, Pearson JD, Torigoe Y, Wang XS, Williams LA, Woodruff JF. Recommendations for including multiple symptoms as endpoints in cancer clinical trials: a report from the ASCPRO (Assessing the Symptoms of Cancer Using Patient-Reported Outcomes) Multisymptom Task Force. Cancer. 2013 Jan 15; 119(2):411-20. PMID: 22930243.
      View in: PubMed
    26. Wang XS, Williams LA, Krishnan S, Liao Z, Liu P, Mao L, Shi Q, Mobley GM, Woodruff JF, Cleeland CS. Serum sTNF-R1, IL-6, and the development of fatigue in patients with gastrointestinal cancer undergoing chemoradiation therapy. Brain Behav Immun. 2012 Jul; 26(5):699-705. PMID: 22251605.
      View in: PubMed
    27. Whitley E, Valverde P, Wells K, Williams L, Teschner T, Shih YC. Establishing common cost measures to evaluate the economic value of patient navigation programs. Cancer. 2011 Aug; 117(15 Suppl):3618-25. PMID: 21780096.
      View in: PubMed
    28. Wang XS, Williams LA, Eng C, Mendoza TR, Shah NA, Kirkendoll KJ, Shah PK, Trask PC, Palos GR, Cleeland CS. Validation and application of a module of the M. D. Anderson Symptom Inventory for measuring multiple symptoms in patients with gastrointestinal cancer (the MDASI-GI). Cancer. 2010 Apr 15; 116(8):2053-63. PMID: 20166216.
      View in: PubMed
    29. Wang XS, Shi Q, Williams LA, Mao L, Cleeland CS, Komaki RR, Mobley GM, Liao Z. Inflammatory cytokines are associated with the development of symptom burden in patients with NSCLC undergoing concurrent chemoradiation therapy. Brain Behav Immun. 2010 Aug; 24(6):968-74. PMID: 20353817.
      View in: PubMed
    30. Lee SJ, Williams LA. Patient-reported outcomes for acute graft-versus-host disease prevention and treatment trials. Biol Blood Marrow Transplant. 2010 Mar; 16(3):295-300. PMID: 19747556.
      View in: PubMed
    31. Loberiza FR, Lee SJ, Freytes CO, Giralt SA, Van Besien K, Kurian S, del Cerro P, Toro JJ, Williams LA, Ketelsen SW, Navarro WH, Rizzo JD. Methodological and logistical considerations to study design and data collection in racial/ethnic minority populations evaluating outcome disparity in hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2009 Aug; 15(8):903-9. PMID: 19589479.
      View in: PubMed
    32. Wang XS, Shi Q, Williams LA, Cleeland CS, Mobley GM, Reuben JM, Lee BN, Giralt SA. Serum interleukin-6 predicts the development of multiple symptoms at nadir of allogeneic hematopoietic stem cell transplantation. Cancer. 2008 Oct 15; 113(8):2102-9. PMID: 18792065.
      View in: PubMed
    33. Krimmel T, Williams LA. Hepatic sinusoidal obstruction syndrome following hematopoietic stem cell transplantation. Oncol Nurs Forum. 2008 Jan; 35(1):37-9. PMID: 18192151.
      View in: PubMed
    34. Williams LA. Clinical management of symptom clusters. Semin Oncol Nurs. 2007 May; 23(2):113-20. PMID: 17512438.
      View in: PubMed
    35. Williams LA. Whatever it takes: informal caregiving dynamics in blood and marrow transplantation. Oncol Nurs Forum. 2007 Mar; 34(2):379-87. PMID: 17573302.
      View in: PubMed
    36. Galbizo E, Williams LA. Chronic graft-versus-host disease. Oncol Nurs Forum. 2006 Sep; 33(5):881-3. PMID: 16986223.
      View in: PubMed
    37. Cohen MZ, Williams L, Knight P, Snider J, Hanzik K, Fisch MJ. Symptom masquerade: understanding the meaning of symptoms. Support Care Cancer. 2004 Mar; 12(3):184-90. PMID: 14735337.
      View in: PubMed
    38. Williams LA. Informal caregiving dynamics with a case study in blood and marrow transplantation. Oncol Nurs Forum. 2003 Jul-Aug; 30(4):679-86. PMID: 12861327.
      View in: PubMed
    39. Williams L, Beveridge RA, Rifkin RM, Bretzel RL, Cuasay L, Alley JL, McGuirk J. Increased pulmonary toxicity results from a 1-day versus 2-day schedule of administration of high-dose melphalan. Biol Blood Marrow Transplant. 2002; 8(6):334-5. PMID: 12108919.
      View in: PubMed
    40. Weiss RB, Rifkin RM, Stewart FM, Theriault RL, Williams LA, Herman AA, Beveridge RA. High-dose chemotherapy for high-risk primary breast cancer: an on-site review of the Bezwoda study. Lancet. 2000 Mar 18; 355(9208):999-1003. PMID: 10768448.
      View in: PubMed
    41. Lonial S, Williams L, Carrum G, Ostrowski M, McCarthy P. Neosartorya fischeri: an invasive fungal pathogen in an allogeneic bone marrow transplant patient. Bone Marrow Transplant. 1997 Apr; 19(7):753-5. PMID: 9156256.
      View in: PubMed
    42. McCarthy PL, Williams L, Harris-Bacile M, Yen J, Przepiorka D, Ippoliti C, Champlin R, Fay J, Blosch C, Jacobs C, Anasetti C. A clinical phase I/II study of recombinant human interleukin-1 receptor in glucocorticoid-resistant graft-versus-host disease. Transplantation. 1996 Sep 15; 62(5):626-31. PMID: 8830827.
      View in: PubMed
    43. Whimbey E, Elting LS, Couch RB, Lo W, Williams L, Champlin RE, Bodey GP. Influenza A virus infections among hospitalized adult bone marrow transplant recipients. Bone Marrow Transplant. 1994 Apr; 13(4):437-40. PMID: 8019468.
      View in: PubMed
    44. Ippoliti C, Williams LA, Huber S. Toxicity of rapidly infused concentrated intravenous immune globulin. Clin Pharm. 1992 Dec; 11(12):1022-6. PMID: 1286551.
      View in: PubMed
    45. Yau JC, LeMaistre CF, Zagars GK, Williams LA, Meneghetti CM, Luke DR, Dunphy FR, Spinolo JA, Jagannath S, Spitzer G, et al. Methylprednisolone, cyclosporine and methotrexate for prophylaxis of acute graft-versus-host disease. Bone Marrow Transplant. 1990 Apr; 5(4):269-72. PMID: 2337738.
      View in: PubMed
    46. Brunner LJ, Luke DR, Lautersztain J, Williams LA, LeMaistre CF, Yau JC. Single-dose cyclosporine pharmacokinetics in various biological fluids of patients receiving allogeneic marrow transplantation. Ther Drug Monit. 1990 Mar; 12(2):134-8. PMID: 2315970.
      View in: PubMed
    47. Luke J, Luke DR, Williams LA, LeMaistre CF, Yau JC. Prevention of cyclosporine-induced nephrotoxicity with transdermal clonidine. Clin Pharm. 1990 Jan; 9(1):49-53. PMID: 2302930.
      View in: PubMed
    48. Longitudinal analysis of patient-reported symptoms post-autologous stem cell transplant and their relationship to inflammation in patients with multiple myeloma. Leukemia and Lymphoma. 56:1335-1341.
    49. Psychosocial issues in chronic graft versus host disease. 314-325.
    50. Higher Stem Cell Dose Infusion after Intensive Chemotherapy Does Not Improve Symptom Burden in Older Patients with Multiple Myeloma and Amyloidosis. Biology of Blood and Marrow Transplantation. 22:226-231.
    51. Prechemotherapy Touch Sensation Deficits Predict Oxaliplatin-Induced Neuropathy in Patients with Colorectal Cancer. Oncology (Switzerland).
    52. Measuring Therapy-Induced Peripheral Neuropathy. Journal of Pain. 16:1032-1043.
    53. Prospective Study of Patient-Reported Symptom Burden in Patients With Non-Small-Cell Lung Cancer Undergoing Proton or Photon Chemoradiation Therapy. Journal of Pain and Symptom Management.
    54. Toxicity of rapidly infused concentrated intravenous immune globulin. American Journal of Hospital Pharmacy. 50.
    55. Establishing common cost measures to evaluate the economic value of patient navigation programs. Cancer. 117:3618-3625.
    56. Patient and health care provider perceptions of cancer-related fatigue and pain. Supportive Care in Cancer. 1-7.
    57. High-dose carmustine, etoposide, cytarabine, cyclophosphamide (BEAC) is feasible in an outpatient community setting for patients (PTS) with relapsed and high-risk non-hodgkin's lymphoma (NHL). Blood. 96.
    WILLIAMS's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description